Enviroxime (LY 122772) is a selective phosphatidylinositol 4-kinase type IIIβ (PI4KB, PI4KIIIβ) inhibitor (IC50 = 60 nM/PI4KB vs. 1.917 µM/PI4KA) with antiviral potency against enteroviruses, including rhinovirus (RV plaque reduction IC50 ≤40 ng/mL; HeLa), poliovirus (PV), coxsackievirus (CV). PI4KB is a host factor essential for enterovirus replication, mutations in viral 3A protein that recruits PI4KB to the replication sites result in enviroxime resistance. Enviroxime is also reported to impede PI4K-independent hepatitis C (HCV) replication at least partially by an inhibitory effect on PI3Ks.
Phosphatidylinositol 4-kinase type IIIβ (PI4KB, PI4KIIIβ) inhibitor with antiviral potency against enteroviruses and hepatitis C (HCV) replication.
Antimicrobial agents and chemotherapy, 59(12), 7782-7785 (2015-09-16)
We investigated the susceptibility of 10 enterovirus D68 (EV-D68) isolates (belonging to clusters A, B, and C) to (entero)virus inhibitors with different mechanisms of action. The 3C-protease inhibitors proved to be more efficient than enviroxime and pleconaril, which in turn
PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases
The Journal of Antimicrobial Chemotherapy, 73, 3375-3384 (2018)
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses
Diabetic Medicine : a Journal of the British Diabetic Association, 37, 1849-1853 (2020)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.